Life science

Immunizing pharma companies

The life sciences, and the pharmaceutical industry in particular, play a vital role in the study and improvement of global (human) health. Currently, several trends and forces are revolutionizing the field and its future. To successfully navigate these waves, companies should prioritize innovation, compliance and sustainable growth. delaware can help you throughout this journey.

Download our leaflet for professionals in the pharmaceutical industry

Explore key trends and challenges in the pharmaceutical industry. Delve into the critical areas of medical device innovation, research & development, regulatory changes, and sustainability, and their profound impact on cost, patient outcomes, and market dynamics.

download

Challenges in the pharmaceutical industry

A variety of disruptive challenges are shaping the field at an alarmingly fast pace. These include the following:

3D printing has uprooted the medical device subindustry by allowing the quick production of customized prosthetics, implants, surgical tools, and more. The technology’s potential is enormous: it can lower costs, improve patient outcomes, and speed up the launch of new medical devices. Life sciences organizations should explore how to use this technology in their current processes, while still ensuring high quality and compliance.
Digital health technologies, such as health apps, are transforming and refining medical treatments. At the same time, the digital transformation is reshaping the discovery, development and commercialization of new drugs. Companies need to enhance their digital capabilities to stay competitive. Following guidelines such as GAMP (Good Automated Manufacturing Practice) is essential to make sure that all solutions are reliable and meet quality standards before they go to market.
Advances in genomics now allow treatments to be customized to a person’s unique genetic profile. To meet new medical needs and maintain a competitive edge, companies have to invest heavily in research and co-development. Partnerships between Site Management Organizations (SMOs), Contract Development and Manufacturing Organizations (CDMOs), Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) are necessary to share costs and risks.

How a leading pharmaceutical company uses GenAI to boost its marketing efficiency

Discover how our innovative Pharma GenAI solutions are revolutionizing marketing in the healthcare industry. Learn more about cutting-edge strategies that enhance engagement and drive success.

read the full story

The cure: our solutions for life sciences

A data-driven approach can help the pharmaceutical industry shift towards patient-centered healthcare, targeted therapies and accelerated drug development. delaware enables organizations to maximize those data – along with AI – in an agile IT landscape, which is essential to tackle top-line and bottom-line hurdles:

Revenue booster shots

Research & Development: Drug discovery and development relies on powerful innovation, driven by advancements in genomics and AI. When done right, the ROI of R&D investments can far exceed the initial expenses.
Specialty drugs offering: Treating rare diseases requires highly specialized medications, which are rare and expensive, but still in high demand. Organizations that invest in such a specialized offering and that grow their market share can earn substantial revenue.
Strategic partnerships in emerging markets: Teaming up with key industry players can help pharmaceutical companies expand their reach and enter new markets.
Exceptional stakeholder experiences: By offering healthcare professionals (HCPs) and patients a seamless omnichannel experience, we ensure access to high-quality content and information, significantly enhancing reach and market potential.

Secure your tried-and-true treatments

Keeping track with regulatory changes: Strict regulations and clinical trials make sure new drugs are safe and efficient. Pharmaceutical companies must stay on top of these developments to adjust their strategies in time and stabilize compliance costs.
Innovating existing treatments: Accelerations in the field of AI, biologics, gene therapy etc. can help organizations further improve and target therapies.
Boosting resilience: the COVID-19 pandemic exposed weaknesses in the pharmaceutical supply chain. Organizations need to invest in their resilience and flexibility to remain profitable in a disruptive global economy.

Cloud technology in biologics

Univercells develops smart technologies for life sciences organizations, so they can produce biotech medicines faster and more cost-effectively – and, as a result, make them easily accessible and affordable for everyone. delaware helped them set up a cloud-based IT landscape to create data-powered harmony across all entities of the biotech group.

read the full story

Why choose delaware?

delaware knows the life sciences and pharmaceutical sector inside out, and our pragmatic approach spans the entire value chain. We understand the sector’s unique pain points and know how to address them through our 20 years of experience and expertise.

delaware uses data and technology to enable and support your innovation and business initiatives. We support you in selecting, developing and leveraging the right technologies that match your needs, by being an end-to-end partner across the entire value stream. From management consultancy to implementation and change management, our in-house teams, supported by a global presence, are equipped to turn your ambitions into reality.